Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Vancouver, British Columbia, February 19, 2026 – TheNewswire –  This press release is being disseminated as required b y National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues (“NI 62-103”). The requirement to provide this disclosure was triggered by an increase in Plantify Foods, Inc.'s (“ Plantify ”) issued and outstanding share capital on February 18, 2026, as a result of the closing of a Private Placement.

Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the  RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation.

MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030

Neve Yarak, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), N2OFF's wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation.

Neve Yarak, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, announced advancement in its European portfolio via its partnership with Solterra Renewable Energy Ltd. (“Solterra”). As announced on December 29, 2025, key milestones in Germany project, which includes solar energy PV and storage assets, have reduced permitting risks, unlocked value through smart capital deployment, and positioned projects for compelling monetization optionality.

Neve Yarak, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, today announced advancement in its European portfolio via its partnership with Solterra Renewable Energy Ltd. (“Solterra”). Key milestones in Germany and Italy have reduced permitting risks, unlocked value through smart capital deployment, and positioned projects for compelling monetization optionality.

Neve Yarak, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF”), a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, following the completion of its acquisition of MitoCareX Bio Ltd., today shared an update from the Chief Executive Officer of MitoCareX, Dr. Alon Silberman, including a shareholder letter that outlines the company's strategic direction, near-term milestones, and development plans within the rapidly expanding precision oncology market.